Roth Mkm Reiterates Buy Rating for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM)‘s stock had its “buy” rating reiterated by Roth Mkm in a note issued to investors on Friday,Benzinga reports. They presently have a $212.00 price target on the biopharmaceutical company’s stock. Roth Mkm’s price objective would indicate a potential upside of 46.73% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Raymond James Financial began coverage on Insmed in a report on Friday, April 10th. They issued an “outperform” rating and a $200.00 price target on the stock. Barclays raised their price objective on Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $166.00 to $212.00 in a report on Monday, March 30th. UBS Group reduced their price objective on Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a report on Tuesday, January 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $213.23.

Insmed Trading Up 1.2%

Shares of NASDAQ INSM opened at $144.48 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The business’s 50 day moving average price is $149.95 and its 200-day moving average price is $167.47. Insmed has a fifty-two week low of $63.81 and a fifty-two week high of $212.75. The company has a market cap of $31.19 billion, a price-to-earnings ratio of -22.54 and a beta of 1.10.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. During the same quarter in the previous year, the company posted ($1.32) earnings per share. The company’s quarterly revenue was up 152.6% compared to the same quarter last year. On average, sell-side analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, COO Roger Adsett sold 88,060 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. This trade represents a 45.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction on Monday, March 30th. The shares were sold at an average price of $150.98, for a total value of $2,964,945.24. Following the sale, the insider directly owned 51,871 shares in the company, valued at $7,831,483.58. This trade represents a 27.46% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 190,476 shares of company stock valued at $29,953,112. 2.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Insmed

A number of institutional investors have recently made changes to their positions in the business. PKO Investment Management Joint Stock Co boosted its position in shares of Insmed by 4.4% in the 1st quarter. PKO Investment Management Joint Stock Co now owns 11,800 shares of the biopharmaceutical company’s stock worth $1,930,000 after purchasing an additional 500 shares in the last quarter. Values First Advisors Inc. boosted its position in shares of Insmed by 7.1% in the 1st quarter. Values First Advisors Inc. now owns 2,203 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 146 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Insmed by 105.4% in the 1st quarter. SG Americas Securities LLC now owns 137,149 shares of the biopharmaceutical company’s stock worth $22,427,000 after purchasing an additional 70,387 shares in the last quarter. KRS Capital Management LLC acquired a new stake in shares of Insmed in the 1st quarter worth $203,000. Finally, Hsbc Holdings PLC boosted its position in shares of Insmed by 8,052.6% in the 4th quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock worth $21,493,000 after purchasing an additional 121,755 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.